PDMR Dealing / Grant of Share Options

RNS Number : 1875M

Oxford BioDynamics PLC

20 May 2022

 

20 May 2022

Oxford BioDynamics Plc

( "OBD" or the "Company" and, together with its subsidiaries, the "Group")

PDMR Dealing / Grant of Share Options

Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch® 3D genomics platform, announces that it has granted a total of 260,000 options over its ordinary shares of 1 pence each ("Ordinary Shares"), to certain Group employees, including 250,000 options to Non-Executive Chairman, Matthew Wakefield, granted under the Company's 2016 Non-Employee Share Option Plan with an exercise price of 17p per share.

One-third of the options granted will vest and become exercisable on the first anniversary of the grant date; one-third on the second anniversary and one-third on the third anniversary.  Vested options will remain exercisable up to and including the tenth anniversary of the date of grant.

Following this grant, Matthew Wakefield, holds options over Ordinary Shares and is interested in Ordinary Shares as follows:

	Total number of options over Ordinary Shares	Ordinary Shares held
		Number	% of current issued share capital
M atthew Wakefield	250,000	625,000	0.62

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which is part of domestic UK law pursuant to the Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310) ("UK MAR"). Upon the publication of this announcement, this inside information (as defined in UK MAR) is now considered to be in the public domain.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Matthew Wakefield
2	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oxford BioDynamics Plc
b)	LEI	2138005Y1TK258O5U928
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 1 pence each ISIN:  GB00BD5H8572
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	250,000 ordinary shares at an exercise price of 17 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	19 May 2022
f)	Place of the transaction	Outside a trading venue

-Ends-

For further details please contact:

Oxford BioDynamics Plc Jon Burrows, CEO Paul Stockdale, CFO	Tel: [phone]
Shore Capital - Nominated Adviser and Broker Advisory: Stephane Auton / John More Broking: Fiona Conroy	Tel: [phone]
Instinctif Partners Melanie Toyne-Sewell / Jonjo Cordey	Tel: [phone] [e-mail]

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is  EpiSwitch® CiRT  (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test,  EpiSwitch ®   CST  (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery,  EpiSwitch® Explorer Array Kit . 

The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial office in Gaithersburg, MD, USA and a reference laboratory in Penang, Malaysia.

For more information, please visit the Company's website,  www.oxfordbiodynamics.com , or follow on  Twitter  or  LinkedIn .

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.

In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.

 

END

 

 

DSHLKLLFLELXBBD